The iPET trial, sponsored by KU Leuven, addresses a significant unmet need in adolescent mental health by targeting emotional distress and anhedonia. With increasing awareness of mental health issues among youth, this intervention could position itself favorably in the growing market for psychological therapies and preventive mental health programs. The competitive landscape includes various behavioral therapies and pharmacological options, but PET's unique focus on positive emotionality may differentiate it. Diligence considerations should include the robustness of the methodology, potential scalability, and the ability to demonstrate long-term efficacy and safety in vulnerable populations.